Flagship Biosciences helps drug developers confidently define their path to success. Our Computational Tissue Analysis (cTA») platform provides the quantitative, contextual tissue interpretation necessary to make timely decisions. With a unique combination of our technology platform, extensive expertise across multiple disciplines (e.g., pathology, biology, image analysis, software engineering), and an in-house CLIA lab, Flagship Biosciences develops quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics, including companion diagnostics (CDx). We collaborate with biopharmaceutical teams at every stage of the clinical trial to: ´ Make informed pipeline decisions that will accelerate the right clinical path ´ Enable critical go/no go decisions based on confirmation of action ´ Design, implement and evaluate prototype diagnostic strategies ´ Differentiate commercial strategies to increase probability of success Over 100 pharmaceutical, biotech, and medical device firms rely on Flagship's technology for success. As the largest clinical tissue-image-analysis operation in the US, Flagship has completed over 400 projects since 2009. Visit flagshipbio.com for more information.